Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-04-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
信息披露事务管理制度（2022年4月修订）
Governance Information Classification · 95% confidence The document is a detailed internal management system for information disclosure of Yifan Pharmaceutical Co., Ltd., including chapters on general principles, content and standards of information disclosure, responsibilities of management, and procedures for disclosure. It references regulatory frameworks such as the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange rules, and covers topics like periodic reports (annual, semi-annual, quarterly), temporary reports, major event disclosures, and internal controls. The document is a comprehensive governance and procedural manual rather than an actual financial report or announcement. It does not contain financial statements, earnings data, or audit opinions, nor is it a transcript or presentation. It is a governance-related document detailing the company's internal rules and practices for information disclosure management. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive governance document.
2022-04-12 Chinese
关于使用自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company (亿帆医药股份有限公司) regarding the use of its own funds to engage in entrusted wealth management (委托理财). It details the investment purpose, amount, risk analysis, risk control measures, board approval, and independent director opinions. The document is a formal public announcement about a financing or investment activity involving the company's capital management, but it does not contain financial statements, earnings data, or audit results. It is not a report or financial statement but an update on capital usage and investment plans. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2295 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-04-12 Chinese
关于继续使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the continued use of idle raised funds for cash management. It details the board and supervisory committee meetings approving the use of temporarily idle raised funds for short-term, low-risk financial products. It includes information about the raised funds, usage progress, risk control measures, and opinions from independent directors and the supervisory board. The document is a formal public announcement about the company's financing fund management activities rather than a financial report or audit. It does not contain financial statements or detailed financial results but focuses on the use of capital and related approvals. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-04-12 Chinese
证券投资专项说明
Regulatory Filings Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's plan to engage in foreign exchange derivative transactions. It discusses the background, necessity, types of transactions, risk analysis, risk management measures, and concludes on the feasibility of such transactions. It is not a financial report like an annual or interim report, nor is it an announcement of voting results, management changes, or legal proceedings. It is a specific report analyzing a financial strategy and risk management related to derivatives, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories and is not a formal financial statement or earnings release.
2022-04-12 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2021 by 亿帆医药股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including detailed descriptions of internal control scope, standards, work performed, and conclusions. The document is a standalone report focused on internal control evaluation, not a full annual report or audit report. It does not appear to be an announcement or a brief notice but a substantive report with detailed content. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document length (8291 characters) supports it being a full report rather than a short announcement. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-12 Chinese
2021年年度审计报告
Audit Report / Information Classification · 98% confidence The document is titled as an "审计报告及财务报表" which translates to "Audit Report and Financial Statements" for the fiscal year 2021. It contains detailed audit opinions, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements. The presence of an auditor's opinion, detailed audit procedures, and comprehensive financial data confirms this is a full audit report with financial statements. The document length is substantial (15,000 characters), indicating it is the full report, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR). FY 2021
2022-04-12 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.